Suzetrigine: A promising analgesic targeting voltage-gated sodium channel

Samarjit Dey, M. V. Eeshwar, Vamshidhar Chamala, Sunit Kumar Gupta

Abstract:

Chronic pain management continues to challenge clinicians due to limitations in efficacy and tolerability of current pharmacological therapies. Suzetrigine, a first-in-class selective sodium channel blocker, has emerged as a promising agent for the treatment of neuropathic and chronic pain syndromes. Preclinical and clinical data highlight suzetrigine's unique sodium channel selectivity, reduced central nervous system side effects, and encouraging efficacy signals in neuropathic pain, trigeminal neuralgia, and refractory pain states. Early-phase trials report favorable safety and tolerability compared to conventional sodium channel blockers. Suzetrigine represents a promising new analgesic agent with a novel mechanism of action. Further Phase 3 studies are warranted to establish its role in pain medicine.

Keywords:

Pain, sodium channel, suzetrigine